Transfusion medicine (Oxford, England) · 2026
The use of fibrinogen concentrate in coagulation testing aids in the diagnosis and management of rare bleeding disorders.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Yang, Zhang Lulu, Lei Zekai, Tang Ning
Аннотация
BACKGROUND: Many clinical laboratories lack the methods or resources to quickly identify rare haemorrhagic diseases, such as genetic/acquired fibrinogen defects and factor XIII deficiency.
CASE REPORT: This report explored the value of human fibrinogen concentrate in the diagnosis and management of rare bleeding disorders through three case studies. Case 1 involved acquired hypofibrinogenemia caused by snake bite, where the coagulation abnormality was corrected by adding fibrinogen in vitro, confirming the mechanism of snake venom-specific degradation of fibrinogen. Case 2 utilised fibrinogen solution to establish a thromboelastography mixing test for rapid diagnosis of autoimmune factor XIII inhibitors. Case 3 improved platelet aggregation function in patients with congenital abnormal fibrinogenaemia through fibrinogen solution.
CONCLUSION: These case studies showed that fibrinogen concentrate may serve as a specific additive to assist in the rapid identification of coagulation dysfunction and guide precise treatment.
CASE REPORT: This report explored the value of human fibrinogen concentrate in the diagnosis and management of rare bleeding disorders through three case studies. Case 1 involved acquired hypofibrinogenemia caused by snake bite, where the coagulation abnormality was corrected by adding fibrinogen in vitro, confirming the mechanism of snake venom-specific degradation of fibrinogen. Case 2 utilised fibrinogen solution to establish a thromboelastography mixing test for rapid diagnosis of autoimmune factor XIII inhibitors. Case 3 improved platelet aggregation function in patients with congenital abnormal fibrinogenaemia through fibrinogen solution.
CONCLUSION: These case studies showed that fibrinogen concentrate may serve as a specific additive to assist in the rapid identification of coagulation dysfunction and guide precise treatment.